🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  2. Ninerafaxstat, Tablet, identical in appearance to ninerafaxstat tablets

    Lacuna Pharma Pty Ltd

    Non-obstructive hypertrophic cardiomyopathy

    phase 2 small molecule active

    1 trial

  3. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  4. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

  5. Novo Nordisk GlucaGen®

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  6. OCALIVA, Placebo for Bezafibrate, Bezalip Mono, Placebo for Obeticholic Acid, Bezalip, OCALIVA

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  7. OCTREOTIDE ACETATE, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Carcinoid Syndrome

    phase 2 small molecule active

    1 trial

  8. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  9. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  10. ONC201

    Jazz Pharmaceuticals Ireland Limited

    Meningioma

    phase 2 small molecule terminated

    1 trial

  11. ONC201

    Jazz Pharmaceuticals Ireland Limited

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  12. ONC201

    Jazz Pharmaceuticals Ireland Limited

    Advanced Glioblastoma

    phase 2 small molecule terminated

    1 trial

  13. ONC201

    Jazz Pharmaceuticals Ireland Limited

    Diffuse Intrinsic Pontine Glioma

    phase 2 small molecule active

    1 trial

  14. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Advanced Pheochromocytoma and Paraganglioma

    phase 2 small molecule active

    1 trial

  15. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  16. ONO-4578

    Ono Pharmaceutical Co.,

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  18. OP-1250

    Olema Pharmaceuticals

    Hormone Receptor Positive Breast Carcinoma

    phase 2 small molecule completed

    1 trial

  19. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  20. ORMD 0801

    ORAMED PHARMACEUTICALS INC.

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  21. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  22. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  23. ORMD-0801 Capsules

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  24. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources